UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 905

Sortiert nach

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

The New England journal of medicine, 2018-02, Vol.378 (6), p.518-528

2018

Link zum Volltext

Verfügbarkeit prüfen

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

Haematologica (Roma), 2014-03, Vol.99 (3), p.511

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Leukemia, 2017-01, Vol.31 (1), p.115-122

2017

Link zum Volltext

Verfügbarkeit prüfen

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

The European journal of health economics, 2020-03, Vol.21 (2), p.219-233

2020

Link zum Volltext

Verfügbarkeit prüfen

Epidemiology of Plasma Cell Leukemia in the Czech Republic

Klinická onkologie, 2019, Vol.32 (1), p.47

2019

Link zum Volltext

Verfügbarkeit prüfen

Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis

Annals of hematology, 2019-04, Vol.98 (4), p.951-962

2019

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

Neoplasma, 2020-01, Vol.67 (1), p.178

2020

Link zum Volltext

Verfügbarkeit prüfen

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE

HemaSphere, 2022-06, Vol.6 (Suppl), p.857-858

2022

Link zum Volltext

Verfügbarkeit prüfen

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

Hematology, Transfusion and Cell Therapy, 2021-10, Vol.43, p.S197-S198

2021

Link zum Volltext

Verfügbarkeit prüfen

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

HemaSphere, 2023-05, Vol.7 (S2), p.5-5

2023

Link zum Volltext

Verfügbarkeit prüfen

EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

Hematology, Transfusion and Cell Therapy, 2020-11, Vol.42, p.257-258

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results

Neoplasma, 2012, Vol.59 (4), p.440

2012

Link zum Volltext

Verfügbarkeit prüfen

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies

Klinická onkologie, 2017, Vol.30 (Supplementum2), p.51-2S59

2017

Link zum Volltext

Verfügbarkeit prüfen

Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation

Klinická onkologie, 2017, Vol.30 (Supplementum2), p.43-2S50

2017

Link zum Volltext

Verfügbarkeit prüfen

Liquid Biopsies - the Clinics and the Molecules

Klinická onkologie, 2017, Vol.30 (Supplementum2), p.13-2S20

2017

Link zum Volltext

Verfügbarkeit prüfen

Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry

Klinická onkologie, 2017, Vol.30 (Supplementum2), p.21-2S28

2017

Link zum Volltext

Verfügbarkeit prüfen

Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients

Leukemia research, 2011-08, Vol.35 (8), p.1008-1013

2011

Link zum Volltext

Verfügbarkeit prüfen

Scleredema associated with multiple myeloma or MGUS: treatment report of four cases

Clinical lymphoma, myeloma and leukemia, 2015-09, Vol.15, p.e207-e207

2015

Link zum Volltext

Verfügbarkeit prüfen

Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance

Neoplasma, 2009, Vol.56 (6), p.526

2009

Link zum Volltext

Verfügbarkeit prüfen

PHENOTYPIC AND MOLECULAR DIFFERENTIATION OF PECTOBACTERIUM AND DICKEYA SPP. CAUSING POTATO TUBER AND STEM ROT IN NORTH-WESTERN PROVINCES OF IRAN

Communications in agricultural and applied biological sciences, 2015, Vol.80 (3), p.611

2015

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma

Klinická onkologie, 2011, Vol.24 Suppl, p.S10-S13

2011

Link zum Volltext

Verfügbarkeit prüfen

Biomarkers in Immunoglobulin Light Chain Amyloidosis

Klinická onkologie, 2017, Vol.30 (Supplementum2), p.60-2S67

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 905

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(718)
Mit Volltextzugriff
(776)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

7 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(508)
Life Sciences & Biomedicine
(388)
Humans
(216)
Biological And Medical Sciences
(143)
Male
(142)
Female
(117)
Fundamental And Applied Biological Sciences. Psychology
(93)
Middle Aged
(90)
Physical Sciences
(86)
Technology
(80)
Adult
(76)
Aged
(76)
Agriculture
(61)
Animals
(60)
Medical Sciences
(59)
Engineering
(52)
Oncology
(49)
Chemistry
(43)
Plant Sciences
(36)
Food Science & Technology
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Vnitřní Lékar̆stvĭ
(43)
Klinická Onkologie
(22)
Aquatic Living Resources
(12)
Neoplasma
(11)
Nippon Suisan Gakkaishi
(11)
Euphytica
(9)
Journal Of Food Science
(9)
Fette, Seifen, Anstrichmittel
(8)
Hemasphere
(8)
Pesticide Biochemistry And Physiology
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)

Circulating serum microRNAs as novel diagnostic and prognostic biomarkers for multiple myeloma and monoclonal gammopathy of undetermined significance

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Methodology and results of real-world cost-effectiveness of carfilzomib in combination with lenalidomide and dexamethasone in relapsed multiple myeloma using registry data

Epidemiology of Plasma Cell Leukemia in the Czech Republic

Simplified novel prognostic score for real-life older adults with multiple myeloma—registry-based analysis

P34 LIGHTHOUSE (OP-108): MELFLUFEN PLUS DARATUMUMAB (DARA) AND DEXAMETHASONE (DEX) VERSUS DARA IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) REFRACTORY TO AN IMMUNOMODULATORY DRUG (IMID) AND A PROTEASOME INHIBITOR (PI) OR HAD RECEIVED ≥3 PRIOR LINES OF THERAPY INCLUDING AN IMID AND A PI

Bortezomib retreatment is effective in relapsed multiple myeloma patients - real-life clinical practice data

P967: TUMOR BURDEN AS A CRITICAL PROGNOSTIC FACTOR OF PRIMARY EXTRAMEDULLARY DISEASE

ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS

B02 CARFILZOMIB AND LENALIDOMIDE‐BASED THERAPY FOR THE TREATMENT OF PRIMARY PLASMA CELL LEUKEMIA: RESULTS OF THE FINAL ANALYSIS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON‐129 STUDY FOR PATIENTS AGED 18‐65 YEARS

B03 CARFILZOMIB AND LENALIDOMIDE FOR PRIMARY PLASMA CELL LEUKEMIA: FINAL RESULTS OF THE PROSPECTIVE PHASE 2 EMN12/HOVON-129 STUDY FOR PATIENTS AGED ≥66 YEARS

EFFICACY AND SAFETY OF CARFILZOMIB, DEXAMETHASONE, DARATUMUMAB TWICE-WEEKLY AT 56 MG/M2 AND ONCE-WEEKLY AT 70 MG/M2 IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: CROSS-STUDY COMPARISON OF CANDOR AND MMY1001

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma--phase II study results

Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies

Czech Registry of Monoclonal Gammopathies - Technical Solution, Data Collection and Visualisation

Liquid Biopsies - the Clinics and the Molecules

Minimal Residual Disease Assessment in Multiple Myeloma by Multiparametric Flow Cytometry

Stem cell marker nestin is expressed in plasma cells of multiple myeloma patients

Scleredema associated with multiple myeloma or MGUS: treatment report of four cases

Phenotype of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance

PHENOTYPIC AND MOLECULAR DIFFERENTIATION OF PECTOBACTERIUM AND DICKEYA SPP. CAUSING POTATO TUBER AND STEM ROT IN NORTH-WESTERN PROVINCES OF IRAN

Multiple myeloma

Biomarkers in Immunoglobulin Light Chain Amyloidosis

Suchergebnisse filtern